YGION Biomedical
YGION Biomedical is dedicated to developing individualized, precision cancer immunotherapies using proprietary technology platforms. Their mission is to create safe, potent, and tailored treatments that activate the patient's immune system to target and eliminate tumors, with a focus on personalized 'plug-and-play' cancer vaccines. They leverage cutting-edge genomics, bioinformatics, and vaccine technology to improve cancer patient outcomes and quality of life.
Industries
Nr. of Employees
small (1-50)
YGION Biomedical
Campus Vienna Biocenter 5, 1030 Vienna, Austria
Products
Lead preclinical individualized neoantigen vaccine program
A preclinical-stage, individualized neoantigen-based vaccine program designed to induce tumor-specific, cell-mediated immune responses via patient-specific peptide neoepitopes delivered on an immune-modulating carrier.
Lead preclinical individualized neoantigen vaccine program
A preclinical-stage, individualized neoantigen-based vaccine program designed to induce tumor-specific, cell-mediated immune responses via patient-specific peptide neoepitopes delivered on an immune-modulating carrier.
Services
Research and development activities to generate patient-specific peptide vaccines, including sequencing, neoepitope selection, peptide synthesis, conjugation to a carrier, and in vivo immunogenicity testing.
Engagement with external partners and participation in industry partnering events to support translational and clinical advancement of individualized immunotherapies.
Research and development activities to generate patient-specific peptide vaccines, including sequencing, neoepitope selection, peptide synthesis, conjugation to a carrier, and in vivo immunogenicity testing.
Engagement with external partners and participation in industry partnering events to support translational and clinical advancement of individualized immunotherapies.
Expertise Areas
- Personalized/individualized cancer vaccines
- Tumor genomics and neoantigen discovery
- Bioinformatics for neoepitope selection
- Peptide vaccine formulation and assembly
Key Technologies
- Next-generation sequencing (NGS)
- Neoantigen prediction and ranking algorithms
- Peptide synthesis
- Peptide-to-carrier conjugation
News & Updates
YGION Biomedical’s team is attending the 7th International Neoantigen Summit from April 29 – May 1, in Amsterdam, Netherlands. This meeting unites the international neoantigen community to overcome neoantigen identification, prediction, and translational challenges that are holding back the full potential of this class of therapies.
YGION Biomedical announced the completion of a Series A financing round of €15 million from an Austrian private trust. The proceeds will be used to further develop YGION’s YGNITE™ technology platform and advance the lead program YG-01 into preclinical and clinical development.
YGION Biomedical GmbH received a significant Life Sciences grant from the Austrian Research Promotion Agency (FFG). This non-dilutive funding will support the development of YGION’s YGNITE™ platform and preclinical development of YG1.
YGION Biomedical’s team is attending the 7th International Neoantigen Summit from April 29 – May 1, in Amsterdam, Netherlands. This meeting unites the international neoantigen community to overcome neoantigen identification, prediction, and translational challenges that are holding back the full potential of this class of therapies.
YGION Biomedical announced the completion of a Series A financing round of €15 million from an Austrian private trust. The proceeds will be used to further develop YGION’s YGNITE™ technology platform and advance the lead program YG-01 into preclinical and clinical development.
YGION Biomedical GmbH received a significant Life Sciences grant from the Austrian Research Promotion Agency (FFG). This non-dilutive funding will support the development of YGION’s YGNITE™ platform and preclinical development of YG1.